652 related articles for article (PubMed ID: 24692732)
1. Full-dose cisplatin and oral vinorelbine concomitant with radiotherapy in unresectable stage III non-small cell lung cancer: a multi-center phase II study.
Juan O; Sánchez-Hernández A; Vázquez S; Casal J; Firvida JL; Aparisi F; Muñoz J; García-Sánchez J; Gironés R; Lázaro M; Giner V
Anticancer Res; 2014 Apr; 34(4):1959-66. PubMed ID: 24692732
[TBL] [Abstract][Full Text] [Related]
2. Oral vinorelbine and cisplatin as induction chemotherapy and concomitant chemo-radiotherapy in stage III non-small cell lung cancer: final results of an international phase II trial.
Krzakowski M; Provencio M; Utracka-Hutka B; Villa E; Codes M; Kuten A; Henke M; Lopez M; Bell D; Biti G; Merimsky O; Beorchia A; Riggi M; Caux NR; Pouget JC; Dubray B; David P
J Thorac Oncol; 2008 Sep; 3(9):994-1002. PubMed ID: 18758302
[TBL] [Abstract][Full Text] [Related]
3. The combination of cisplatin and vinorelbine with concurrent thoracic radiation therapy for locally advanced stage IIIA or IIIB non-small-cell lung cancer.
Hirose T; Mizutani Y; Ohmori T; Ishida H; Hosaka T; Ando K; Shirai T; Okuda K; Ohnishi T; Horichi N; Kubota H; Adachi M
Cancer Chemother Pharmacol; 2006 Sep; 58(3):361-7. PubMed ID: 16331494
[TBL] [Abstract][Full Text] [Related]
4. Induction chemotherapy with cetuximab, vinorelbine-cisplatin followed by thoracic radiotherapy and concurrent cetuximab, vinorelbine-cisplatin in patients with unresectable stage III non-small cell lung cancer.
Liu D; Zheng X; Chen J; Liu G; Xu Y; Shen Y; Xie L; Zhao W; Jiang G; Fan M
Lung Cancer; 2015 Sep; 89(3):249-54. PubMed ID: 26118463
[TBL] [Abstract][Full Text] [Related]
5. Oral vinorelbine and cisplatin with concurrent radiotherapy after induction chemotherapy with cisplatin and docetaxel for patients with locally advanced non-small cell lung cancer: the GFPC 05-03 study.
Descourt R; Vergnenegre A; Barlesi F; Lena H; Fournel P; Falchero L; Berard H; Hureaux J; Le Caer H; Chavaillon JM; Geriniere L; Monnet I; Chouabe S; Robinet G;
J Thorac Oncol; 2011 Feb; 6(2):351-7. PubMed ID: 21164367
[TBL] [Abstract][Full Text] [Related]
6. Oral vinorelbine and cisplatin with concomitant radiotherapy in stage III non-small cell lung cancer (NSCLC): a feasibility study.
Beckmann G; Fietkau R; Huber RM; Kleine P; Schmidt M; Semrau S; Aubert D; Fittipaldo A; Flentje M
Onkologie; 2006 Apr; 29(4):137-42. PubMed ID: 16601369
[TBL] [Abstract][Full Text] [Related]
7. Phase I study of concurrent high-dose three-dimensional conformal radiotherapy with chemotherapy using cisplatin and vinorelbine for unresectable stage III non-small-cell lung cancer.
Sekine I; Sumi M; Ito Y; Horinouchi H; Nokihara H; Yamamoto N; Kunitoh H; Ohe Y; Kubota K; Tamura T
Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):953-9. PubMed ID: 21377282
[TBL] [Abstract][Full Text] [Related]
8. S-1 plus cisplatin with concurrent radiotherapy for locally advanced non-small cell lung cancer: a multi-institutional phase II trial (West Japan Thoracic Oncology Group 3706).
Ichinose Y; Seto T; Sasaki T; Yamanaka T; Okamoto I; Takeda K; Tanaka M; Katakami N; Sawa T; Kudoh S; Saka H; Nishimura Y; Nakagawa K; Fukuoka M
J Thorac Oncol; 2011 Dec; 6(12):2069-75. PubMed ID: 22052226
[TBL] [Abstract][Full Text] [Related]
9. Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer: a randomized study.
Zatloukal P; Petruzelka L; Zemanova M; Havel L; Janku F; Judas L; Kubik A; Krepela E; Fiala P; Pecen L
Lung Cancer; 2004 Oct; 46(1):87-98. PubMed ID: 15364136
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of concurrent thoracic radiotherapy in combination with weekly paclitaxel plus carboplatin in locally advanced non-small cell lung cancer: LOGIK0401.
Takayama K; Inoue K; Tokunaga S; Matsumoto T; Oshima T; Kawasaki M; Imanaga T; Kuba M; Takeshita M; Harada T; Shioyama Y; Nakanishi Y
Cancer Chemother Pharmacol; 2013 Dec; 72(6):1353-9. PubMed ID: 24166107
[TBL] [Abstract][Full Text] [Related]
11. A phase II study of hyperfractionated accelerated radiotherapy (HART) after induction cisplatin (CDDP) and vinorelbine (VNR) for stage III non-small-cell lung cancer (NSCLC).
Ishikura S; Ohe Y; Nihei K; Kubota K; Kakinuma R; Ohmatsu H; Goto K; Niho S; Nishiwaki Y; Ogino T
Int J Radiat Oncol Biol Phys; 2005 Mar; 61(4):1117-22. PubMed ID: 15752891
[TBL] [Abstract][Full Text] [Related]
12. GILT--A randomised phase III study of oral vinorelbine and cisplatin with concomitant radiotherapy followed by either consolidation therapy with oral vinorelbine and cisplatin or best supportive care alone in stage III non-small cell lung cancer.
Flentje M; Huber RM; Engel-Riedel W; Andreas S; Kollmeier J; Staar S; Dickgreber N; Vaissiere N; De Almeida C; Edlich B; Fietkau R
Strahlenther Onkol; 2016 Apr; 192(4):216-22. PubMed ID: 26809652
[TBL] [Abstract][Full Text] [Related]
13. Phase II trial of oral vinorelbine in combination with cisplatin followed by consolidation therapy with oral vinorelbine in advanced NSCLC.
Lena MD; Ramlau R; Hansen O; Lorusso V; Wagner L; Barni S; Cristovao MM; Huber R; Alberola V; Mitrovic M; Colin C; Gasmi J
Lung Cancer; 2005 Apr; 48(1):129-35. PubMed ID: 15777980
[TBL] [Abstract][Full Text] [Related]
14. Concurrent chemoradiotherapy with vinorelbine and a platinum compound followed by consolidation chemotherapy for unresectable stage III non-small cell lung cancer: preliminary results of a phase II study.
Rusu P; Ciuleanu TE; Cernea D; Pelau D; Gaal V; Cebotaru C; Guttman T; Todor N; Ghilezan N
J BUON; 2007; 12(1):33-9. PubMed ID: 17436399
[TBL] [Abstract][Full Text] [Related]
15. Oral vinorelbine plus cisplatin as first-line chemotherapy in nonsquamous non-small-cell lung cancer: final results of an International randomized phase II study (NAVotrial 01).
Bennouna J; Havel L; Krzakowski M; Kollmeier J; Gervais R; Dansin E; Serke M; Favaretto A; Szczesna A; Cobo M; Ciuffreda L; Jassem J; Nicolini M; Ramlau R; Amoroso D; Melotti B; Almodovar T; Riggi M; Caux NR; Vaissière N; Tan EH
Clin Lung Cancer; 2014 Jul; 15(4):258-65. PubMed ID: 24954228
[TBL] [Abstract][Full Text] [Related]
16. Concurrent cetuximab and radiotherapy after docetaxel-cisplatin induction chemotherapy in stage III NSCLC: satellite--a phase II study from the Swedish Lung Cancer Study Group.
Hallqvist A; Wagenius G; Rylander H; Brodin O; Holmberg E; Lödén B; Ewers SB; Bergström S; Wichardt-Johansson G; Nilsson K; Ekberg L; Sederholm C; Nyman J
Lung Cancer; 2011 Feb; 71(2):166-72. PubMed ID: 20541833
[TBL] [Abstract][Full Text] [Related]
17. A phase II study of cisplatin and 5-fluorouracil with concurrent hyperfractionated thoracic radiation for locally advanced non-small-cell lung cancer: a preliminary report from the Okayama Lung Cancer Study Group.
Segawa Y; Ueoka H; Kiura K; Kamei H; Tabata M; Sakae K; Hiraki Y; Kawahara S; Eguchi K; Hiraki S; Harada M
Br J Cancer; 2000 Jan; 82(1):104-11. PubMed ID: 10638975
[TBL] [Abstract][Full Text] [Related]
18. Intensified high-dose chemoradiotherapy with induction chemotherapy in patients with locally advanced non-small-cell lung cancer-safety and toxicity results within a prospective trial.
Pöttgen C; Eberhardt WE; Gauler T; Krbek T; Berkovic K; Jawad JA; Korfee S; Teschler H; Stamatis G; Stuschke M
Int J Radiat Oncol Biol Phys; 2010 Mar; 76(3):809-15. PubMed ID: 19427744
[TBL] [Abstract][Full Text] [Related]
19. Induction chemotherapy with triweekly docetaxel and cisplatin followed by concomitant chemoradiotherapy with or without surgery in stage III non-small-cell lung cancer: a phase II study.
Aydiner A; Sen F; Saglam EK; Oral EN; Eralp Y; Tas F; Toker A; Dilege S
Clin Lung Cancer; 2011 Sep; 12(5):286-92. PubMed ID: 21729649
[TBL] [Abstract][Full Text] [Related]
20. Randomized phase II trial of uracil/tegafur and cisplatin versus vinorelbine and cisplatin with concurrent thoracic radiotherapy for locally advanced unresectable stage III non-small-cell lung cancer: NJLCG 0601.
Sugawara S; Maemondo M; Tachihara M; Inoue A; Ishimoto O; Sakakibara T; Usui K; Watanabe H; Matsubara N; Watanabe K; Kanazawa K; Ishida T; Saijo Y; Nukiwa T;
Lung Cancer; 2013 Jul; 81(1):91-6. PubMed ID: 23643176
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
